Argenx stock hits all-time high at 716.89 USD

Argenx NV ADR stock has reached an all-time high, climbing to 716.89 USD. The biotech company, now valued at $43.3 billion, has demonstrated remarkable growth with revenues surging 88% over the last twelve months to $3.1 billion. This milestone reflects the company’s strong performance over the past year, during which the stock has appreciated by 35.58%. The surge in value underscores investor confidence and the company’s robust market position, with analysts maintaining a "Strong Buy" consensus and seeing up to 52% upside potential. As Argenx continues to innovate and expand its portfolio, its stock performance remains a point of interest for market analysts and investors alike. This latest high marks a significant achievement for the company, highlighting its growth trajectory in the competitive biotech sector. InvestingPro analysis reveals 14 additional key insights about Argenx’s financial health and market position.

In other recent news, argenx SE has announced positive results from its Phase 3 ADAPT SERON trial for its drug Vyvgart, targeting seronegative generalized myasthenia gravis (gMG) patients. The trial met its primary endpoint, showing clinical improvement across all patient subtypes. This success has prompted several analysts to adjust their outlooks on the company. Piper Sandler raised its price target for argenx to $820, maintaining an Overweight rating, while JPMorgan reiterated its Overweight rating with a EUR730.00 price target. Oppenheimer also reiterated an Outperform rating, setting a price target of $778.00, highlighting the drug’s statistical significance on the MG-ADL measurement scale. RBC Capital not only reiterated its Outperform rating with an $850.00 price target but also initiated coverage, noting the drug’s meaningful benefits across all antibody status subtypes in myasthenia gravis patients. These developments underscore the growing confidence in argenx’s Vyvgart treatment among analysts.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.